Debarshi Ghosh’s Post

Stories making headlines today in the biopharma industry: Merck's CMO, Eliav Barr, has declared the organization's intention to magnify its immunology pipeline through further deals, specifically focusing on cardiometabolic drugs and immunology. In other news, GSK has pledged to purchase Aiolos Bio, a clinical-stage asthma drugmaker, for a hefty $1.4 billion. This development has facilitated one of the swiftest startup reveal-to-acquisition journeys in biotech history, as Aiolos Bio was only unveiled three months ago, bolstered by the backing of a number of renowned investors. Meanwhile, rumors indicating a possible acquisition of the biotechnology company Cytokinetics by Novartis have been downplayed by the latter's CEO, Vas Narasimhan. In an interview with CNBC, he emphasized Novartis' focus on smaller, "$5 billion or less" assets, debunking the alleged buyout speculation. On another note, radiopharma firm Lantheus has initiated collaboration with Perspective Therapeutics, investing $28M upfront to secure an exclusive licensing deal directed towards an alpha-targeted therapy for neuroendocrine tumors. This move is set to extend its hand even further in the radiopharma sphere and solidify its presence in this field. #pharma #biotech #topstories #biodatastudio

#BreakingNews. Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD). “Sanofi is a proven leader in developing therapeutics for rare neuromuscular diseases and is the ideal partner to maximize the opportunity and reach of losmapimod outside the U.S.,” said Alex C. Sapir, Fulcrum’s president and chief executive officer. “This deal aligns with our core strategy, allowing Fulcrum to remain focused on preparations for commercialization of losmapimod in the U.S., while leveraging Sanofi’s exceptional global commercial capabilities and established infrastructure in key markets around the world. We are excited about the potential to provide the first approved treatment for FSHD patients, and we look forward to working with Sanofi to bring losmapimod to patients globally.” Learn more from our press release: https://ow.ly/I4jQ50REel8 #FSHD #FSHDawareness #Biotech #FulcrumTherapeutics #healthinnovations #newsalert

🚀Spotlight on Innovation: Supporting Release Therapeutics' Drug Development Breakthrough We're thrilled to share the significant strides made by Release Therapeutics (formerly MaxiVax) in their recent publication in iScience. Their groundbreaking work on the Myo-P device, leveraging Genoskin’s non-clinical services, is setting new benchmarks in therapeutic protein delivery and immune response mobilization. Release Therapeutics' commitment to innovation, combined with the use of our HypoSkin® human skin models, has enabled a leap forward in drug development. This collaboration underscores the effectiveness of HypoSkin® in mirroring true human responses, marking a crucial step towards enhancing biocompatibility assessments and the overall efficacy of new therapies. By focusing on reducing the dependency on animal testing, this partnership not only accelerates the path to groundbreaking therapies but also aligns with our shared vision of a more ethical and efficient drug development process. Congratulations to the Release Therapeutics team on this remarkable achievement. Genoskin is proud to support your journey, offering our advanced technologies and services to foster the next generation of medical breakthroughs. #drugdevelopment #safety #bioavailability #drugdeliverysystem #localtolerance Read the publication here  https://bit.ly/3JdJrN6

What Role Does Innovation in #BreastCancerTreatment Play in the Market's Expansion? The growth of the #biosimilarmonoclonalantibody market is primarily propelled by rising breast cancer prevalence, increased awareness of early diagnosis, and the adoption of innovative #breastcancertreatment options. Biologic therapies, such as monoclonal antibodies, have transformed disease treatment due to their superior efficacy and specificity compared to conventional small molecule drugs. Nevertheless, their high production expenses lead to costly treatments, restricting patient access. As a result, addressing cost barriers is essential to ensure broader availability and affordability of these life-saving therapies. Key Market Players: Celltrion Healthcare Co.,Ltd., Teva Pharmaceuticals , Pfizer., Novartis, Amgen., BIOCAD, Biogen, Coherus BioSciences, Shanghai Henlius Biotech, Inc., Biocon Want to Know More: https://lnkd.in/dAfaf7j4 #AMR #MonoclonalAntibodies #Biosimilars #BreastCancerTreatment #InnovationInMedicine #CancerAwareness #PatientAccess #BiologicTherapies #MedicalAdvancements #HealthcareCosts #DiseaseTreatment 

I hope everyone had a lovely Christmas break with their loved ones & are enjoying the holiday break 🎅🌲🎉🤶 Below are some exciting updates which have taken place within the Biotech/Pharma industry over the holiday period 🚨 🚨 🚨 🍾 - Bristol Myers Squibb have agreed to acquire Karuna Therapeutics for $14 Billion & now strengthens it's Neuroscience Portfolio. ✅ 🍾 - AstraZeneca have decided to acquire Gracell Biotechnologies for $1.2 Billion, furthering their cell therapy ambition across Oncology and Autoimmune Diseases.✅ 🍾 - Bristol Myers Squibb have also decided to acquire RayzeBio for $4.1 Billion to bolster its cancer drug business, marking the second multi-billion dollar deal struck by the drugmaker in less than a week.✅ 🍾 - Sudo Biosciences have secured $116 Million to starts clinical trials of its oral & topical TYK2 patients - congrats to Scott Byrd.✅ 🍾 - Eli Lilly and Company enters AI deal with Fauna Bio to discover novel obesity targets, the two teams will collaborate to identify multiple drug targets - congrats to Ashley Zehnder.✅ 🍾 - The FDA granted full approval to Swedish drugmaker Calliditas Therapeutics to treat rare kidney disease IgA Nephropathy (IgAN) - congrats to Renee Aguiar-Lucander. ✅ 🍾 - GSK have gained rights to Jiangsu Hansoh Pharmaceutical Group Co., Ltd. ADC Candidate in a deal worth more than $1.7 Billion.✅ 🍾 - First Wave BioPharma, Inc. have decided Acquire ImmunogenX to Bolster it's Gastrointestinal-Focused Pipeline .✅ #Elixir #IndustryUpdates #Biotechnology #Pharma #News #FDA #Mergers #ClinicalTrials #Approvals #Announcements

I sat down with C&EN during #JPM2024 – the premier week for life science dealmaking – to discuss our pioneering work in targeted protein degradation. We explored the importance of strategic partnerships in accelerating our progress in this new modality, which could reshape what is possible for patients in need. At Astellas Pharma, we are combining our capabilities with the expertise of ambitious innovators to advance the development of targeted protein degraders capable of effectively treating more diseases in more patients. You can read the full article here: http://bit.ly/48BcGV2 #Changingtomorrow #ScienceFirstForPatients

💊 𝑻𝒉𝒆 𝑳𝒊𝒇𝒆 𝑺𝒄𝒊𝒆𝒏𝒄𝒆 𝒊𝒏𝒅𝒖𝒔𝒕𝒓𝒚 𝒊𝒔 𝒄𝒐𝒏𝒔𝒕𝒂𝒏𝒕𝒍𝒚 𝒄𝒉𝒂𝒏𝒈𝒊𝒏𝒈 𝒂𝒏𝒅 𝒊𝒕'𝒔 𝒉𝒂𝒓𝒅 𝒕𝒐 𝒌𝒆𝒆𝒑 𝒖𝒑 𝒘𝒊𝒕𝒉 𝒕𝒉𝒆 𝒍𝒂𝒕𝒆𝒔𝒕 𝒏𝒆𝒘𝒔 𝒂𝒏𝒅 𝒕𝒓𝒆𝒏𝒅𝒔 𝒕𝒉𝒆𝒔𝒆 𝒅𝒂𝒚𝒔. 𝑰𝒇 𝒚𝒐𝒖’𝒅 𝒍𝒊𝒌𝒆 𝒕𝒐 𝒔𝒕𝒂𝒚 𝒊𝒏𝒇𝒐𝒓𝒎𝒆𝒅, 𝒈𝒊𝒗𝒆 𝒎𝒆 𝒂 𝒇𝒐𝒍𝒍𝒐𝒘 𝒂𝒔 𝑰’𝒍𝒍 𝒃𝒆 𝒈𝒊𝒗𝒊𝒏𝒈 𝒚𝒐𝒖 𝒎𝒚 𝒕𝒐𝒑 10 𝑳𝒊𝒇𝒆 𝑺𝒄𝒊𝒆𝒏𝒄𝒆 𝒊𝒏𝒅𝒖𝒔𝒕𝒓𝒚 𝒖𝒑𝒅𝒂𝒕𝒆𝒔 𝒘𝒆𝒆𝒌𝒍𝒚 𝒕𝒐 𝒌𝒆𝒆𝒑 𝒂𝒏 𝒆𝒚𝒆 𝒐𝒏! 👇 1.     Analysts predict myeloma market will hit $33B by 2030 with Bristol Myers Squibb and Johnson & Johnson leading the race. 2.     AbbVie's Skyrizi regains top pharma TV ad spender title in May 💵 3.     Eli Lilly and Company's tirzepatide showcases superior phase 2 results to placebo for MASH resolution with more than half of patients achieving improvement in fibrosis at 52 weeks.  4.     Merck & Co. to acquire eye-focused drug developer EyeBio for a value of up to $3bn 🤝 5.     Amgen Phase III positive results positions Uplizna for Label Expansion in Rare Autoimmune Disease 6.     Nestlé’s health arm to buy the rights to Seres Therapeutics’ Vowst, the first-ever fecal transplant pill 💊 7.     Novo Nordisk braces for generic challenge to its diabetes drug Ozempic and weight-loss treatment Wegovy in China 8.     GSK shares fall 9% in the wake of reopening Zantac lawsuits 📉 9.     Investigators highlight promising potential for Moderna/MSD’s cancer vaccine, mRNA-4157, to transform the melanoma landscape 10.  FDA advisory panel votes against Lykos Therapeutics’ pioneer MDA therapy for PTSD citing concerns with the effectiveness and risks of the treatment. ❌ #LifeScience #Pharma #biotechnology #news #updates IRLCA Limited

#Article: When it comes to #biotech M&A, the rumor mill can be hit-or-miss. Case in point: Following rumors last week of a potential acquisition of Mirati Therapeutics by Sanofi, days later Bristol Myers Squibb ultimately emerged as the victor, paying $4.8 billion for Mirati’s oncology-focused assets. Following a sluggish summer of deals, we’ve seen a string of buyouts. But will this trend continue? So far, the first two weeks of October have seen a flurry of activity with four deals worth about $6.7 billion in total. While #BMS’s $4.8 billion buy of #Mirati was the by far the biggest, this month we also saw AbbVie acquire neurodegenerative disease-focused Mitokinin Inc for $110 million, Eli Lilly and Company’s $1.4 billion purchase of radiopharmaceutical company POINT Biopharma and Kyowa Kirin International plc.’s $387 million acquisition of gene therapy developer Orchard Therapeutics.  While there’s been a recent uptick in deals, #bankruptcy among #biotechs is also on the rise. In fact, 2023 has seen a record high number of biotech bankruptcies, BioSpace reported this week—along with a spike in the number of cases in the past couple of years.  Among the drivers: the #postCOVID economy, a shift toward data-driven financing activity and inflation rates. On the opposite end of the spectrum, one company that continues its upward financial trajectory is Novo Nordisk, fuelled by #diabetes drug #Ozempic and #weightlossmedication #Wegovy. On Friday, the Danish drugmaker for the third time this year raised its full-year sales guidance. Earlier this week, Novo halted a Phase III kidney outcomes study of semaglutide—the active ingredient in Ozempic and Wegovy—ahead of schedule due to strong efficacy signals. Read more from #BioSpace 👇🏼 https://lnkd.in/ezDgYnRT

Stories making headlines today in the biopharma industry: In recent biotech industry news, Moderna has indicated potential losses and is crafting their strategic path back to profitability, with a focus shift from early-stage research to emphasizing their ongoing Phase III programmes. Similarly, C4 Therapeutics, as part of cost-cutting measures, has made the difficult decision to lay off 30% of its staff. Their plan from this point is to concentrate resources on programs with the most promise for value creation and patient impact. On the partnership front, Coherus Biosciences is exiting a TIGIT pact with Chinese company Junshi, just three months after buying Surface Oncology. The optimism is palpable at Catalent, where plans are in place to manufacture GLP-1 drugs, spurred by their rising stock price. They are ambitiously targeting GLP-1 and gene therapies to bolster this year's revenue. News from Aclaris offers a bit of a mixed bag: their JAK inhibitor demonstrated varied results during a Phase IIb eczema study. They are now actively seeking a partner to propel the study's next steps. Fundraising efforts at Myrobalan Therapeutics - a biotech company focusing on the central nervous system - have proved fruitful, raising $24 million in its Series A round. These funds will be directed towards advancing their four CNS therapeutic candidates into clinical trials, ultimately helping neurodegenerative patients either repair or restore functions. Alcon, an eye care specialist, has announced a Phase III victory for their dry eye drug and anticipates filing for FDA authorization by mid-2024. In retail pharmacy news, the new CEO of Walgreens has delineated their survival strategy as a standalone business. The CEO expressed confidence in the feasibility of operating their UK component, Boots, separately, despite ongoing talks of a split. Finally, the legal dispute between LinkedUp, TianTi, and Adimab over a yeast-based antibody platform is now settled. Stay tuned for more updates as these stories develop in the dynamic landscape of the global biotech industry. #pharma #biotech #topstories #biodatastudio

Elevating #DrugDevelopment with Precision-Crafted Cyclized Peptides At Mimotopes, we're driven by the belief that the next breakthrough in healthcare can come from anywhere – and anyone. That's why we're dedicated to empowering researchers and developers with the tools they need to transform innovative concepts into life-changing treatments. Among the myriad of tools in the pharmaceutical toolkit, #cyclizedpeptides hold a special place. Their remarkable stability, high specificity, and reduced toxicity make them pivotal in the development of next-generation therapeutics. From immunosuppressants like #Cyclosporine to diabetes treatments such as #Exenatide, cyclized peptides are forging new paths in drug development. 💡 Why Cyclized Peptides? - Stability & Specificity: Their cyclic structure offers enhanced stability and specificity, crucial for targeting complex biological processes. - Versatility: From cancer to autoimmune diseases and beyond, cyclized peptides are versatile tools in addressing a broad spectrum of therapeutic needs. - Innovation Potential: They represent a frontier of innovation, especially in areas where traditional therapies fall short. At Mimotopes, we stand ready to support your journey from concept to clinic. Our commitment is to provide: - Custom Synthesis: Tailored cyclized peptides with the modifications and purity levels your research demands. - Unmatched Quality: Each peptide is synthesized with an unwavering focus on achieving the highest purity and bioactivity. - Collaborative Support: We don't just supply peptides; we partner with you, offering expertise to help navigate the complexities of drug development. Whether you're exploring novel treatments for chronic diseases or searching for the next breakthrough in immunotherapy, Mimotopes is your ally. Let's push the boundaries of what's possible together. Mimotopes #DrugDevelopment #CyclizedPeptides #Innovation #PharmaceuticalResearch